NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis

Company Overview

NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for central nervous system (CNS) disorders and acute neurological injuries. Utilizing a proprietary target discovery platform that integrates bioinformatics, multi-omics analyses and functional screening, the company identifies key drivers of neuronal damage and repair. Its lead candidate, NB-01, is a humanized monoclonal antibody targeting pathways involved in neuroinflammation and axonal growth, currently in Phase 1b clinical trials for acute ischemic stroke.

Beyond NB-01, the NeuroBo pipeline includes preclinical programs such as NB-02, which seeks to address neuropathic pain through modulation of P2X ion channels, and NB-03, aimed at slowing progression in certain neurodegenerative diseases. The company leverages partnerships with academic institutions and research centers to enhance its discovery capabilities and accelerate preclinical candidate selection. Its platform approach enables rapid validation of novel targets and the development of biologics with potential applications across a range of CNS indications.

Headquartered in Cambridge, Massachusetts, NeuroBo Pharmaceuticals serves patients globally through collaborative research and development efforts in North America and Asia. The company is led by an experienced team of neuroscientists and biotech executives dedicated to advancing new treatments for unmet needs in neurology. Through its integrated discovery and development model, NeuroBo seeks to translate scientific insights into transformative therapies for individuals affected by central nervous system disorders.

Key Stats

• Today's Range: $0.68 to $0.70
• 50-Day Range: $0.60 to $0.74
• 52-Week Range: $2.08 to $4.41
• Volume: 29,031 shs
• Average Volume: 39,605 shs
• Market Capitalization: $6.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NRBO Stock Analysis - Frequently Asked Questions

How have NRBO shares performed this year?

NeuroBo Pharmaceuticals' stock was trading at $2.03 at the beginning of the year. Since then, NRBO stock has decreased by 65.7% and is now trading at $0.6959.

How were NeuroBo Pharmaceuticals' earnings last quarter?

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) issued its earnings results on Thursday, November, 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.27.

When did NeuroBo Pharmaceuticals' stock split?

NeuroBo Pharmaceuticals's stock reverse split on the morning of Thursday, December 21st 2023.The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of NeuroBo Pharmaceuticals?

Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeuroBo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroBo Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), GE Aerospace (GE) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 9/15/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Banking
• Current Symbol: NASDAQ:NRBO
• CIK: 1638287
• Web: www.neurobopharma.com
• Phone: (857) 702-9600
• Fax: 734-293-0444
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -189.12%
• Return on Assets: -122.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.41
• Quick Ratio: 2.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.50 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 8,616,000
• Free Float: 8,526,000
• Market Cap: $6.00 million
• Optionable: Not Optionable
• Beta: -0.26